History
3.0 Leap of the GC Genome
2023
-“GreenBiome® Lady” released.
2022
– Expansion of GC Genome’s Yongin branch.
– Release of “Hair Loss Risk Screen.“
– Patent registration for “Detection Method and Use Thereof for Chromosomal Abnormalities Based on Whole Genome Sequencing.”
– Designation of Clinical Trial Sample Analysis Facility (GCLP) by the Ministry of Food and Drug Safety (MFDS).
– GC Genome’s company name changed.
– Approval of “GreenPlan® HRD,” the first domestically approved HRD advanced medical technology
2.0. Growth of the GC genome
2021
-Selected as one of the “Top 10 Leading Companies” in the Ministry of Trade,
Industry and Energy’s Global Innovation Competition for Medium-sized Enterprises.
-Launch of “Telorisq®,” a test for measuring aging speed.
-Expansion of testing facilities and establishment of data centers.
-Release of “GreenPlan® HRD” for assessing recombination deficiency.
2020
-Release of “GreenBiome® Perio&Denti” for oral microbiome testing.
-Launch of “Diagnostic Whole Genome Sequencing (DGS) Test.”
2019
-Release of “GreenBiome®” for gut microbiome testing.
-Patent registration for “Liquid Biopsy Core Technology.”
-Domestic launch of “Guardant360®” liquid biopsy test.
2018
-Relocation of [Cell center] -Launch of “Risk Screen,” a genetic test for identifying genetic factors associated with disease susceptibility in health screenings.
2017
-Acquisition of “NGS Clinical Laboratory Certification” from the Ministry of Food and Drug Safety (MFDS).
-Obtained certification from the College of American Pathologists (CAP).
1.0. Birth of the GC Genome
2016
-Acquisition of patent for “G-NIPT® proprietary algorithm.” -Release of newborn genomic screening test “i-screen®.”
2015
-Launch of “Drug Suitability DNA” test.
-Obtained “Grade A Accuracy Evaluation for Genetic Testing” from the Korean Genetic Testing Evaluation Institute.
-Release of non-invasive prenatal chromosomal abnormality screening test “G-NIPT®.”
2014
-New release of genomic analysis test items.
> “Diagnostic Exome Sequencing (DES) Test
> Type 1 Myotonic Dystrophy | ProtectMe® Women’s Cancer.”
2013
-Establishment of Green Cross Genome Research Institute as a corporate-affiliated entity.
-Establishment of Green Cross Genome corporation
